Literature DB >> 18639330

Prognostic implication of endometriosis in clear cell carcinoma of the ovary.

J P Orezzoli1, A H Russell, E Oliva, M G Del Carmen, J Eichhorn, A F Fuller.   

Abstract

OBJECTIVE: The aim of this study is to investigate whether the presence of endometriosis is a prognostic factor in patients diagnosed with clear cell carcinoma (CCC) of the ovary.
METHODS: Retrospective chart review was performed to all patients diagnosed with CCC and endometriosis between 1975 and 2002. All pathology reports were reviewed and slides were reviewed when available. Cox regression analysis and Kaplan-Meier test were used to calculate survival prognostic factors. The level of significance was set at 0.05.
RESULTS: Eighty-four patients with CCC were identified with a 49% rate of coexisting endometriosis. Patients with tumors arising in endometriosis (n=15), with endometriosis found elsewhere in the specimen (n=26), and those without endometriosis (n=43) were analyzed comparatively. Patients with CCCs arising in endometriosis were 10 years younger (95% C.I. 0.6-18 years) than those with CCC not arising in endometriosis (P<0.05). Patients with endometriosis anywhere in the surgical specimen presented at early stage 66% of the times versus 42% for patients without endometriosis (P<0.05). Median overall survival (OS) for patients with endometriosis was 196 months (95% C.I. 28-363) versus 34 months (95% C.I. 13-55) for patients without endometriosis (P=0.01). Advanced tumor stage at diagnosis (HR 13, 95% C.I. 5-29, P=0.001) and absence of endometriosis (HR 2, 95% C.I. 1-3.9, P=0.03) were the only significant prognostic factors associated with poor survival. Disease recurrence or death among optimally and completely cytoreduced patients was 31% and 59% for those with and without endometriosis respectively (P>0.05).
CONCLUSIONS: Our study suggests that the presence of endometriosis in patients with CCC of the ovary is associated with progression free and OS advantages with no difference in initial resectability.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18639330     DOI: 10.1016/j.ygyno.2008.05.025

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  21 in total

1.  Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.

Authors:  Seiji Mabuchi; Chiaki Kawase; Deborah A Altomare; Kenichirou Morishige; Masami Hayashi; Kenjiro Sawada; Kimihiko Ito; Yoshito Terai; Yukihiro Nishio; Andres J Klein-Szanto; Robert A Burger; Masahide Ohmichi; Joseph R Testa; Tadashi Kimura
Journal:  Mol Cancer Ther       Date:  2010-07-27       Impact factor: 6.261

2.  Role of endometriosis as a prognostic factor for post-progression survival in ovarian clear cell carcinoma.

Authors:  Hiroki Ishibashi; Masashi Takano; Morikazu Miyamoto; Hiroaki Soyama; Hiroko Matsuura; Tadashi Aoyama; Tomoyuki Yoshikawa; Kento Kato; Hitoshi Tsuda; Kenichi Furuya
Journal:  Mol Clin Oncol       Date:  2017-10-23

3.  Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013.

Authors:  A Oseledchyk; M M Leitao; J Konner; R E O'Cearbhaill; D Zamarin; Y Sonoda; G J Gardner; K Long Roche; C A Aghajanian; R N Grisham; C L Brown; A Snyder; D S Chi; R A Soslow; N R Abu-Rustum; O Zivanovic
Journal:  Ann Oncol       Date:  2017-12-01       Impact factor: 32.976

4.  Caveolin-1-ACE2 axis modulates xenobiotic metabolism-linked chemoresistance in ovarian clear cell carcinoma.

Authors:  Arulkumar Nagappan; Ki-Hyung Kim; Yuseok Moon
Journal:  Cell Biol Toxicol       Date:  2022-05-27       Impact factor: 6.819

5.  mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.

Authors:  Seiji Mabuchi; Chiaki Kawase; Deborah A Altomare; Kenichirou Morishige; Kenjiro Sawada; Masami Hayashi; Masahiko Tsujimoto; Mareo Yamoto; Andres J Klein-Szanto; Russell J Schilder; Masahide Ohmichi; Joseph R Testa; Tadashi Kimura
Journal:  Clin Cancer Res       Date:  2009-08-18       Impact factor: 12.531

Review 6.  Endometriosis-associated Malignancy.

Authors:  N Krawczyk; M Banys-Paluchowski; D Schmidt; U Ulrich; T Fehm
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-02       Impact factor: 2.915

7.  MUC4 gene polymorphisms associate with endometriosis development and endometriosis-related infertility.

Authors:  Cherry Yin-Yi Chang; Hui-Wen Chang; Chih-Mei Chen; Chia-Ying Lin; Chih-Ping Chen; Chih-Ho Lai; Wei-Yong Lin; Hsing-Ping Liu; Jim Jinn-Chyuan Sheu; Fuu-Jen Tsai
Journal:  BMC Med       Date:  2011-02-24       Impact factor: 8.775

8.  Pathogenesis of ovarian clear cell adenofibroma, atypical proliferative (borderline) tumor, and carcinoma: clinicopathologic features of tumors with endometriosis or adenofibromatous components support two related pathways of tumor development.

Authors:  Chengquan Zhao; Lee Shu-Fune Wu; Ross Barner
Journal:  J Cancer       Date:  2011-02-21       Impact factor: 4.207

9.  Association Between Endometriosis and Prognosis of Ovarian Cancer: An Updated Meta-Analysis.

Authors:  Peng Chen; Chi-Yuan Zhang
Journal:  Front Oncol       Date:  2022-03-31       Impact factor: 6.244

Review 10.  The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life.

Authors:  Giovanni Grandi; Angela Toss; Laura Cortesi; Laura Botticelli; Annibale Volpe; Angelo Cagnacci
Journal:  Biomed Res Int       Date:  2015-08-30       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.